Translating a Preclinical Hydrogel Platform into a Human Therapeutic for Delivering Targeted Low-Dose Anti-CTLA-4
Gels · 02.06.2026 · 12 (6) · 489
DOI: 10.3390/gels12060489 ↗Kurz gefasst
Fachartikel in der Zeitschrift Gels, online erschienen am 02.06.2026. Verfasst von Airi Harui und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary & Critical Care, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095-1690, USA. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of California, Los Angeles, UCLA.
Abstract (Originalsprache)
Systemic administration of antibodies that target immune checkpoint inhibitor pathways is a highly effective approach to cancer immunotherapy, but systemic toxicity can limit clinical utility. In preclinical testing, a peri-tumor injection of a low dose of hydrogel-encapsulated cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibody was shown to selectively activate T cells in tumor-draining lymph nodes, induce tumor infiltration by cytotoxic T cells, and result in tumor regression, protective immunity, and long-term survival. In contrast to systemic therapy, there was limited systemic exposure or risk for autoimmune toxicity. The current study focuses on translating this platform into a biocompatible human therapeutic. The hydrogel matrix was reformulated using a low-molecular-weight hyaluronic acid. A recombinant human hyaluronidase (rHuPH20) was incorporated to promote lymph node targeting and self-resorbing features. Formulations were optimized to operate at neutral pH and with gelation kinetics allowing a 5 to 10 min administration window. Performance features were assessed including the capacity to encapsulate human IgG or ipilimumab antibody at proposed therapeutic doses (1–15 mg/mL), impact of rHuPH20 and antibody on rheologic properties and three-dimensional microstructure, and payload delivery profiles in vitro and in vivo. Results confirm the capacity for this unique hydrogel platform to be adapted for human testing.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Pulmonary & Critical Care, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095-1690, USA.
ORCID-Profile: Airi Harui, Michael D Roth
Förderung
- University of California, Los Angeles
- UCLA
Zitieren
APA
Harui, A., & Roth, M. D. (2026). Translating a Preclinical Hydrogel Platform into a Human Therapeutic for Delivering Targeted Low-Dose Anti-CTLA-4. Gels, 12(6), 489. https://doi.org/10.3390/gels12060489
Vancouver
Harui A, Roth MD. Translating a Preclinical Hydrogel Platform into a Human Therapeutic for Delivering Targeted Low-Dose Anti-CTLA-4. Gels. 2026;12(6):489. doi:10.3390/gels12060489
BibTeX
@article{Harui2026,
author = {Harui, Airi and Roth, Michael D},
title = {Translating a Preclinical Hydrogel Platform into a Human Therapeutic for Delivering Targeted Low-Dose Anti-CTLA-4},
journal = {Gels},
year = {2026},
volume = {12},
number = {6},
pages = {489},
doi = {10.3390/gels12060489}
}
EUVIMED